Royce & Associates LP Aerie Pharmaceuticals Inc Transaction History

Royce & Associates LP

  • $10.5 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 04, 2022
SELL
$4.95 - $9.16 $110,385 - $204,268
-22,300 Closed
0 $0
Q2 2021

Aug 06, 2021
SELL
$15.16 - $18.97 $1.45 Million - $1.81 Million
-95,350 Reduced 81.05%
22,300 $357,000
Q1 2021

May 10, 2021
BUY
$13.12 - $20.9 $1.54 Million - $2.46 Million
117,650 New
117,650 $2.1 Million

Others Institutions Holding AERI

# of Institutions
3
Shares Held
2.4M
Call Options Held
0
Put Options Held
0
View Full List

About AERIE PHARMACEUTICALS INC

AERI Quotes by TradingView
  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email